article thumbnail

STAT+: Novo asks FDA to bar compounders from making Ozempic copies

STAT

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make. The FDA still has to make a decision on whether to officially place semaglutide on the lists.

article thumbnail

Opinion: The FDA’s risky action on compounding weight loss drugs

STAT

Confronted with the public outcry, the FDA took an unusual step: It allowed pharmacies to continue making their own copies of the drug through the practice of pharmacy compounding, selling it at a fraction of Makena’s price.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period

STAT

The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.

article thumbnail

As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle

STAT

The move was a clear warning to compounders that they can no longer make copycat versions of the drugs — a process that is only permitted when the medications are on an official agency shortage list. Read the rest…

article thumbnail

STAT+: Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s

STAT

The deal marks a noteworthy development for Ro, which has been one of the major telehealth platforms providing compounded copies of GLP-1 obesity drugs during shortages of the branded treatments. Continue to STAT+ to read the full story…

article thumbnail

STAT+: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list

STAT

A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list.

article thumbnail

STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy

STAT

judge dismissed its lawsuit accusing a compound pharmacy of selling versions of its Wegovy and Ozempic medicines, which are widely prescribed for weight loss and have become franchise products for the drug company. The drug maker argued the compounders were selling versions of its medicines that were never approved by the U.S.